Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor

Kawai, Hideki; Saito, Yasutoshi; Demura, Ryo; Odaka, Hidesato; Takahashi, Susumu; Takahashi, Kazuaki; Kurokawa, Hirokazu; Enomoto, Katsuhiko

doi:10.1111/1759-7714.12592

Cited by 3 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICI monotherapy or ICIs in combination with chemotherapy have previously been applied to the treatment of patients with inoperable advanced NSCLC, and after the confirmation of tumor reductions, surgery was performed and no tumor cells were detected 7–11 . The present case had more extensive disease and was older than these cases.…”

Section: Discussionmentioning

confidence: 67%

“…[1][2][3][4][5][6] ICI monotherapy or ICIs in combination with chemotherapy have previously been applied to the treatment of patients with inoperable advanced NSCLC, and after the confirmation of tumor reductions, surgery was performed and no tumor cells were detected. [7][8][9][10][11] The present case had more extensive disease and was older than these cases. Although surgery after immunochemotherapy is controversial, it is appropriate because the affected area may be excised and subjected to a histopathological examination.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5][6] In addition, cases of inoperable advanced non-small cell lung cancer (NSCLC) that became operable with ICIs or ICIs in combination with chemotherapy and achieved a complete response (CR) have previously been reported. [7][8][9][10][11] However, further research is needed on the combination of ICIs and chemotherapy as induction therapy for advanced NSCLC because their efficacy and safety have not yet been established.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient

et al. 2021

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have caused a paradigm shift in the treatment of lung cancer. Here, we encountered a case of inoperable locally advanced squamous cell carcinoma of the lung that became operable with pembrolizumab-based immunochemotherapy and achieved a pathological complete response. An 82-yearold man suspected of having lung cancer was referred to our hospital. The patient was clinically diagnosed with left upper lobe squamous cell carcinoma cT2aN3M0 c-stage IIIC. Immunostaining revealed the expression of programmed death-ligand 1 in 60% of tumor cells. The cancer cells disappeared after two cycles of chemotherapy with carboplatin and nanoparticle albumin-bound paclitaxel plus pembrolizumab. As the abnormal accumulation of 18 F-fluorodeoxyglucose (FDG) on FDG-positron emission tomography/computed tomography before chemotherapy almost disappeared after pembrolizumab-based immunochemotherapy, left upper lobectomy and lymph node dissection were performed. No cancer cells were pathologically detected from the resected tissue. Therefore, ICIs combined with chemotherapy may enable inoperable advanced lung cancer patients to undergo surgery and achieve a complete response.K E Y W O R D S advanced squamous cell carcinoma of the lung, immune checkpoint inhibitor, induction immunochemotherapy, pathological complete response

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As a result, it is critical to investigate relevant prognostic indicators and treatment targets for LUSC. Because of the variability and complexity of the tumor immune microenvironment, immunotherapy benefits only a tiny percentage of patients [9][10][11][12]. Glycolysis underlies the proliferation and differentiation of malignant tumors, provides energy for tumor metabolism, and is considered to be an important factor contributing to tumors [13].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma

Kadasah

2024

IJMS

View full text Add to dashboard Cite

Lung squamous cell carcinoma (LUSC) is one of the most common malignancies. There is growing evidence that glycolysis-related genes play a critical role in tumor development, maintenance, and therapeutic response by altering tumor metabolism and thereby influencing the tumor immune microenvironment. However, the overall impact of glycolysis-related genes on the prognostic significance, tumor microenvironment characteristics, and treatment outcome of patients with LUSC has not been fully elucidated. We used The Cancer Genome Atlas (TCGA) dataset to screen glycolysis-related genes with prognostic effects in LUSC and constructed signature and nomogram models using Lasso and Cox regression, respectively. In addition, we analyzed the immune infiltration and tumor mutation load of the genes in the models. We finally obtained a total of glycolysis-associated DEGs. The signature model and nomogram model had good prognostic power for LUSC. Gene expression in the models was highly correlated with multiple immune cells in LUSC. Through this analysis, we have identified and validated for the first time that glycolysis-related genes are highly associated with the development of LUSC. In addition, we constructed the signature model and nomogram model for clinical decision-making.

show abstract

“…In the adverse events from induction chemotherapy, careful attention should be paid to myelosuppression, and anemia in particular, among cases of transfusion rejection. Recently, some surgical reports and clinical trials have described the benefits of induction therapy with immune checkpoint inhibitors in lung cancer [21][22][23]. In the future, this may represent an effective option for tumor down-staging and avoiding extensive surgery.…”

Section: Discussionmentioning

confidence: 99%

Our experience of lung resection in patients who decline blood transfusion for religious reasons

Takagi

Muto

Yamaguchi

et al. 2021

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Objective Surgical treatment for patients who refuse blood transfusion due to religious beliefs is an important issue related to medical safety. Few reports have examined pulmonary surgery for these patients, and we analyzed clinical characteristics in such cases. Methods Ten Jehovah’s Witness (JW) patients with lung tumor resection who declined blood transfusion for religious reasons between December 2013 and February 2020 at the Fukushima Medical University Hospital were included. Median total intraoperative blood loss was 17.5 mL (range 5–150 mL). Fibrin glue was used intraoperatively for 8 patients. Final pathological examination revealed pulmonary adenocarcinoma in 9 cases and metastasis of bladder cancer in 1 case. In 8 patients with pulmonary adenocarcinoma examined for epidermal growth factor receptor (EGFR) gene mutation, 6 cases showed mutation. No patients had serious complications, but 1 patient displayed temporary anemia due to postoperative hemorrhagic gastrointestinal ulcer. Result and conclusions Our findings confirm that pulmonary resection is feasible and safe for JW patients if performed by experienced medical staff. However, awareness of complications associated with perioperative bleeding is important. Each JW patient should be interviewed individually and every available perioperative option aimed at blood-sparing management, including use of blood coagulation factors and fibrinogen concentrates, should be carefully discussed and clarified. In this study, the EGFR gene mutation rate was higher than usual for cases of lung adenocarcinoma. Further studies are necessary to assess clinical features in JW patients with lung cancer.

show abstract

Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor

Cited by 3 publications

References 6 publications

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient

Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma

Our experience of lung resection in patients who decline blood transfusion for religious reasons

Contact Info

Product

Resources

About